Analysts think BIIB stock price could increase by 21%
Jun 03, 2025, 11:25 AM
1.53%
What does BIIB do
Biogen, headquartered in Cambridge, Massachusetts, specializes in therapies for neurological diseases, employing 7,570 people and offering treatments for conditions like MS, SMA, Alzheimer's, and ALS. Their product portfolio includes TECFIDERA, SPINRAZA, and collaborations on LEQEMBI and others.
33 analysts think BIIB stock price will increase by 20.58%. The current median analyst target is $158.10 compared to a current stock price of $131.12. The lowest analysts target is $116.15 and the highest analyst target is $273.00.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.